Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionet TherapeuticsROCO:7808 -0.17%10 Days Inventory is 113.02 as of Dec. 2025, which is 64% above its 10-year median of 68.79. GuruFocus rates ROCO:7808 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 638 Biotechnology companies, Bionet Therapeutics ranks better than 65.2% on this metric.
The historical rank and industry rank for Bionet Therapeutics's Days Inventory or its related term are showing as below:
ROCO:7808'
s Days Inventory Range Over the Past 10 Years
Min: 38.02 Med: 68.79 Max: 120.36
Current: 120.36
During the past 4 years, Bionet Therapeutics's highest Days Inventory was 120.36. The lowest was 38.02. And the median was 68.79.
ROCO:7808's Days Inventory is ranked better than 65.2% of 638
companies
in the Biotechnology industry
Industry Median: 182.245
vs ROCO:7808: 120.36
Bionet Therapeutics's Days Inventory
increased
from Dec. 2024 (88.80) to Dec. 2025 (113.02).
It might indicate that Bionet Therapeutics's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Bionet Therapeutics's Inventory Turnover for the
six
months ended in Dec. 2025 was 1.61.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bionet Therapeutics's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.34.
Bionet Therapeutics (ROCO:7808) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Bionet Therapeutics's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bionet Therapeutics's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Bionet Therapeutics Days Inventory Related Terms
Bionet Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Bionet Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7808 vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Bionet Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionet Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bionet Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Bionet Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionet Therapeutics (ROCO:7808) has a Days Inventory of 113.02 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Bionet Therapeutics and its competitors. This is 64% above median its historical median of 68.79. Over the past decade, Bionet Therapeutics' Days Inventory has ranged from 38.02 to 120.36. According to the industry distribution chart, Bionet Therapeutics ranks #222 out of 638 companies in the Biotechnology industry, placing it in the top 34.8%.
Is Bionet Therapeutics' Days Inventory too high?
Bionet Therapeutics' current Days Inventory of 113.02 is 64% above median its 10-year median of 68.79. Over the past 10 years, this metric has ranged from a low of 38.02 to a high of 120.36. The Biotechnology industry median Days Inventory is 182.25. Bionet Therapeutics' value of 113.02 is 38% below this industry median. Based on the distribution chart, Bionet Therapeutics ranks #222 out of 638 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bionet Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bionet Therapeutics ranks #222 out of 638 companies for Days Inventory. This puts Bionet Therapeutics in the upper half of its industry. The industry median Days Inventory is 182.25. Bionet Therapeutics' value of 113.02 is 38% below this benchmark. Historically, Bionet Therapeutics' own Days Inventory has ranged from 38.02 to 120.36 over the past decade. While the company's 10-year median is 68.79 vs. the industry median of 182.25, Bionet Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 182.25, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionet Therapeutics's current Days Inventory of 113.02 is 38% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Bionet Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 182.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionet Therapeutics's current Days Inventory is 113.02, which is 64% above median its own 10-year median of 68.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current Days Inventory of 113.02. The current Days Inventory is 113.02, which is 64% above median its 10-year median of 68.79 and 38% below the Biotechnology industry median of 182.25. Bionet Therapeutics' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current Days Inventory is 113.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
10GF Score
Get the complete analysis for ROCO:7808
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7808 has been successfully added to your 
